Global Folic Acid Injection Market Size By Type (Folic Acid Inj 5mg/ml, Folic Acid Inj 30mg/2ml), By Application (Elderly, Children), By Region, And Segment Forecasts, 2023 to 2032

The Global Folic Acid Injection Market was valued at USD 1.3 billion in 2023 and is anticipated to reach USD 2.1 billion by 2031, growing at a CAGR of 6.0% during the forecast period (2023–2031). This growth is primarily driven by increasing awareness of folate deficiency, rising prevalence of anemia and malnutrition, and the growing demand for injectable nutritional therapies in clinical and emergency settings. Folic acid injections play a critical role in treating folate-deficiency anemia, supporting prenatal health, and addressing vitamin B9 deficiency in individuals with poor gastrointestinal absorption.

Drivers:

Rising Prevalence of Folate Deficiency and Anemia:

The growing number of individuals affected by anemia, particularly in developing regions, is significantly driving the demand for folic acid injections. This trend is further supported by nutritional deficiencies caused by poor diets and gastrointestinal disorders that impair folate absorption.

Increasing Maternal Health Initiatives:

Governmental and non-governmental programs focused on improving maternal and neonatal health are increasingly incorporating folic acid supplementation, especially via injections in high-risk pregnancies, fueling market growth.

Growth in Clinical Nutrition and Geriatric Healthcare:

With aging populations worldwide, the demand for parenteral nutrition solutions is rising. Folic acid injections are commonly used in elderly patients who have difficulty absorbing nutrients from oral supplements, further boosting market demand.

Restraints:

Availability of Oral Alternatives:

Widespread availability and preference for oral folic acid supplements among patients and physicians limit the market potential for injectable forms in mild to moderate deficiency cases.

Strict Regulatory Approvals:

Folic acid injections fall under stringent regulatory frameworks, especially in the U.S. and Europe, where clinical trial requirements, pharmacovigilance obligations, and manufacturing controls can delay product approvals and market entry.

Opportunity:

Expansion in Underserved and Emerging Markets:

Low-income and rural areas with high incidences of nutritional deficiencies present untapped growth opportunities. Partnerships with public health agencies and community healthcare providers can boost access and adoption.

Development of Combination Therapies:

Innovations in combining folic acid with other essential nutrients like vitamin B12 and iron in injectable formulations are gaining traction. These advanced formulations cater to patients with multiple deficiencies and support faster therapeutic outcomes.

Market by System Type Insights:

The Single-Drug Injection segment held the largest market share in 2023. It remains the preferred form due to its targeted approach for treating folate deficiency in clinical and emergency settings. However, the Combination Therapy Injections segment is projected to exhibit the highest CAGR during the forecast period, driven by the rising need for multi-nutrient therapies in malnourished populations and antenatal care.

Market by End-use Insights:

In 2023, the Hospitals segment dominated the market, accounting for over 45% of the total revenue. Hospitals continue to be the primary administration centers for injectable therapies due to their advanced diagnostic capabilities and access to acute care patients. The Home Healthcare segment is expected to grow significantly, supported by increasing home-based treatment preferences and the availability of trained caregivers for administering injections.

Market by Regional Insights:

Asia-Pacific led the global folic acid injection market in 2023, driven by a high prevalence of anemia, growing maternal healthcare programs, and expanding public health initiatives in countries like India, China, and Indonesia. North America is expected to register steady growth due to strong healthcare infrastructure and increasing awareness of micronutrient deficiencies among the elderly and pregnant women.

Competitive Scenario:

Key players in the global folic acid injection market include Pfizer Inc., Fresenius Kabi AG, Sandoz (Novartis), Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Mylan N.V., Baxter International Inc., Cipla Ltd., Zydus Lifesciences Ltd., and Wockhardt Ltd. These companies focus on geographic expansion, cost-effective generic manufacturing, and innovation in combination drug delivery.

Recent Developments:

2023: Fresenius Kabi launched a new low-cost folic acid injectable formulation for government-funded nutrition programs in Africa.

2024: Teva Pharmaceuticals received FDA approval for its generic combination of folic acid and vitamin B12 injectable solution.

2025: Cipla expanded its injectable product line in Southeast Asia with WHO prequalification for folic acid solutions used in maternal health programs.

Scope of Work – Global Folic Acid Injection Market

FAQs:

What is the current market size of the Global Folic Acid Injection Market?

The market was valued at USD 1.3 billion in 2023.

What is the major growth driver of the Global Folic Acid Injection Market?

The primary driver is the rising prevalence of folate deficiency and anemia, particularly in developing regions.

Which is the largest region during the forecast period in the Global Folic Acid Injection Market?

Asia-Pacific is the largest and fastest-growing regional market.

Which segment accounted for the largest market share in the Global Folic Acid Injection Market?

The Single-Drug Injection segment held the largest share in 2023.

Who are the key market players in the Global Folic Acid Injection Market?

Key players include Pfizer Inc., Fresenius Kabi, Sandoz, Teva Pharmaceuticals, and Cipla Ltd.